Goldman Sachs Group Inc (NYSE:GS) added the health care service provider McKesson Corporation (NYSE:MCK) to its conviction buy list. According to Goldman, the market is not fully realizing McKesson’s “outsized earnings potential post its acquisition of a more than 75% stake in Celesio, and expanded distribution contract with RAD.” In addition, Goldman sees a lot of future upside synergy benefits from Celesio.Celesio AG (ETR:CLS1) is a Germany pharmaceutical distribution holding company. The price target was raised to $215 a share from $208.